Published in Oncoimmunology on December 21, 2014
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology (2015) 0.85
Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology (2015) 0.84
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84
Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83
Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology (2015) 0.83
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology (2015) 0.82
Doubling the blockade for melanoma immunotherapy. Oncoimmunology (2015) 0.80
Gastric cancer: The times they are a-changin'. World J Gastrointest Oncol (2015) 0.79
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology (2015) 0.77
Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. Oncoimmunology (2016) 0.76
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol (2010) 2.24
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol (2014) 1.77
Cutaneous melanoma. Lancet (2013) 1.73
Hemophilia A induced by ipilimumab. N Engl J Med (2011) 1.55
Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res (2014) 1.54
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res (2013) 1.51
Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother (2011) 1.47
Combination checkpoint blockade--taking melanoma immunotherapy to the next level. N Engl J Med (2013) 1.45
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
Abscopal effect in a patient with melanoma. N Engl J Med (2012) 1.39
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med (2009) 1.30
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
Ipilimumab. Nat Rev Drug Discov (2011) 1.20
Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res (2013) 1.16
Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med (2013) 1.15
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract (2014) 1.13
Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
Nivolumab: a review of its use in patients with malignant melanoma. Drugs (2014) 1.05
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.05
Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology (2014) 1.01
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology (2013) 1.01
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology (2013) 1.01
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells. Oncoimmunology (2013) 0.99
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2014) 0.96
Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96
Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96
Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology (2013) 0.96
Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology (2014) 0.95
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95
The immune landscape of human tumors: Implications for cancer immunotherapy. Oncoimmunology (2014) 0.94
Update on immune checkpoint inhibitors in lung cancer. Cancer Control (2014) 0.94
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. Oncoimmunology (2014) 0.93
Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. Oncoimmunology (2014) 0.92
Current trends of anticancer immunochemotherapy. Oncoimmunology (2013) 0.91
Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91
Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90
Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology (2013) 0.90
Inhibiting the inhibitors: Checkpoints blockade in solid tumors. Oncoimmunology (2013) 0.87
Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol (2013) 0.87
A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway. Oncoimmunology (2014) 0.87
Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology (2014) 0.86
Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology (2014) 0.85
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology (2014) 0.84
Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. Oncoimmunology (2013) 0.83
Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies. Oncoimmunology (2013) 0.83
High frequency of T cells specific for cryptic epitopes in melanoma patients. Oncoimmunology (2013) 0.82
Immune correlates of melanoma survival in adoptive cell therapy. Oncoimmunology (2013) 0.82
Melanoma: immune checkpoint blockade story gets better. Lancet (2014) 0.81
Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy. Nat Rev Drug Discov (2010) 0.80
Novel insights into the mechanism of action of lenalidomide. Oncoimmunology (2014) 0.79
Melanoma: smart therapeutic strategies in immuno-oncology. Nat Rev Clin Oncol (2014) 0.79
Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts. Oncoimmunology (2014) 0.79
Immunological checkpoint inhibitors enter adolescence. Lancet Oncol (2013) 0.78
Biomarkers and correlative endpoints for immunotherapy trials. Am Soc Clin Oncol Educ Book (2013) 0.78
Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. Oncoimmunology (2013) 0.78
Immune response markers in sentinel nodes may predict melanoma progression. Oncoimmunology (2014) 0.77
Intensifying tumour immunity through combination therapy. Lancet Oncol (2012) 0.76
Treatment of advanced melanoma with immunological checkpoint block. Curr Oncol Rep (2011) 0.76
Improved survival ends nivolumab trial early. Cancer Discov (2014) 0.76
Immunity unleashed in melanoma. Lancet Oncol (2010) 0.76
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01
Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91
Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90
Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology (2015) 0.84
Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology (2015) 0.83
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology (2015) 0.77